<DOC>
	<DOCNO>NCT01402882</DOCNO>
	<brief_summary>The CRASH-3 trial provide reliable evidence effect tranexamic acid mortality disability patient traumatic brain injury . The effect tranexamic acid risk vascular occlusive event seizure also assess . Additionally , nest study conduct subset CRASH-3 trial participant . This nested study ( CRASH-3 Intracranial Bleeding Sub-Study [ CRASH-3 IBS ] ) examine effect tranexamic acid intracranial haemorrhage cerebral ischaemia use CT Scans approximately 1,000 patient randomise CRASH-3 trial .</brief_summary>
	<brief_title>Clinical Randomisation Antifibrinolytic Significant Head Injury</brief_title>
	<detailed_description>BACKGROUND : Worldwide , 10 million people kill hospitalised traumatic brain injury ( TBI ) year . About 90 % death TBI occur low middle income country . TBI mostly affect young adult many experience long lasting permanent disability . The social economic burden TBI considerable . Tranexamic acid ( TXA ) commonly give surgical patient reduce bleed need blood transfusion . TXA show reduce number patient receive blood transfusion third , reduces volume blood transfuse one unit , half need surgery control bleed elective surgical patient . More recently , CRASH-2 trial show administration TXA within 8 hour injury significantly reduce death due bleeding ( RR=0.85 , 95 % CI 0.76-0.96 ; p=0.008 ) , all-cause mortality ( RR=0.91 , 95 % CI 0.85-0.97 ; p=0.0035 ) , apparent increase vascular occlusive event . A meta-analysis randomise control trial TXA TBI show significant reduction haemorrhage growth ( OR=0.61 , 95 % CI 0.41 0.91 ) mortality ( OR=0.59 , 95 % CI 0.35 0.99 ) TXA . Although result trial promise , estimate imprecise data effect TXA disability . Additionally , nest study conduct subset CRASH-3 trial participant . This nested study ( CRASH-3 Intracranial Bleeding Sub-Study [ CRASH-3 IBS ] ) examine effect tranexamic acid intracranial haemorrhage cerebral ischaemia use CT Scans approximately 1,000 patient randomise CRASH-3 trial . AIM : The CRASH-3 trial provide reliable evidence effect tranexamic acid mortality disability patient TBI . The effect TXA risk vascular occlusive event seizure also assess . PRIMARY OUTCOME : The primary outcome death hospital ( within 28 day injury ) patient randomise within 3 hour injury ( cause death described ) . SECONDARY OUTCOMES : 1 . Vascular occlusive event ( myocardial infarction , stroke , pulmonary embolism , clinical evidence deep vein thrombosis ) 2 . In hospital disability assess use Disability Rating Scale Patient Orientated Outcome 3 . Seizures 4 . Neurosurgical intervention 5 . Days intensive care Other adverse event describe Other Outcome Measures : CRASH-3 IBS Primary outcome - total volume intracranial haemorrhage randomisation , adjust baseline haemorrhage volume . Secondary outcome - - Frequency progressive haemorrhage : number patient post-randomisation CT scan total haemorrhage volume 25 % volume pre-randomisation scan ; - Frequency delay haemorrhage : number patient haemorrhage post-randomisation CT scan one pre-randomisation scan ; - New focal ischaemic lesion : ischaemic lesion appear post-randomisation CT scan pre-randomisation scan ; - Total volume intracranial bleeding patient undergo surgical evacuation haemorrhage randomisation , adjust volume baseline bleeding . TRIAL DESIGN : A large , pragmatic , randomise , double blind , placebo control trial among 13,000 traumatic brain injury patient DIAGNOSIS AND INCLUSION/EXCLUSION CRITERIA : Adults traumatic brain injury - within eight hour injury - intracranial bleeding CT scan GCS 12 less , - significant extra-cranial haemorrhage The fundamental eligibility criterion responsible clinician 's 'uncertainty ' whether use tranexamic acid particular patient traumatic brain injury . TEST PRODUCT , REFERENCE THERAPY , DOSE AND MODE OF ADMINISTRATION : A load dose tranexamic acid ( 1 gram intravenous injection ) placebo ( sodium chloride 0.9 % ) give soon possible randomisation . A maintenance dose tranexamic acid ( 1 gram intravenous injection ) placebo ( sodium chloride 0.9 % ) give load dose finish . SETTING : This trial coordinate London School Hygiene &amp; Tropical Medicine ( University London ) conduct worldwide hospital low , middle high income country .</detailed_description>
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Brain Injuries</mesh_term>
	<mesh_term>Tranexamic Acid</mesh_term>
	<mesh_term>Antifibrinolytic Agents</mesh_term>
	<criteria>Adults traumatic brain injury within eight hour injury ( limited within 3 hour September , 2016 ) intracranial bleed CT scan GCS 12 less , significant extracranial haemorrhage The fundamental eligibility criterion responsible clinician 's 'uncertainty ' whether use tranexamic acid particular patient traumatic brain injury The fundamental eligibility criterion responsible clinician 's 'uncertainty ' whether use tranexamic acid particular patient traumatic brain injury</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>traumatic brain injury</keyword>
	<keyword>tranexamic acid</keyword>
	<keyword>antifibrinolytic</keyword>
	<keyword>randomise</keyword>
	<keyword>clinical trial</keyword>
</DOC>